L 304
Alternative Names: L-304Latest Information Update: 31 Jan 2025
Price :
$50 *
At a glance
- Originator Neutrolis Therapeutics
- Class Eye disorder therapies
- Mechanism of Action Extracellular trap inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry eyes
Most Recent Events
- 23 Dec 2024 Neutrolis Therapeutics in-licenses the rights to intellectual property that covers the use of topical DNase enzymes in the eye from University of Illinois Chicago
- 23 Dec 2024 Preclinical trials in Dry eyes in USA (Topical) before December 2024 (Neutrolis Therapeutics pipeline, December 2024)